Aptevo Therapeutics Inc. announced that APVO436, in combination with venetoclax and azacitidine, achieved a 100% clinical benefit rate (CBR) in venetoclax treatment naïve AML patients. The data, which was presented in a poster session at the 64thAmerican Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, also showed that APVO436, when given in combination with this standard-of-care regimen, was observed to be generally safe and well tolerated.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.989 USD | -12.48% | +40.07% | -87.58% |
Apr. 11 | US Equity Markets Close Mixed After March Producer Price Inflation Data | MT |
Apr. 11 | Top Midday Decliners | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.58% | 1.59M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- APVO Stock
- News Aptevo Therapeutics Inc.
- Aptevo Therapeutics Inc. Announces APVO436, in Combination with Venetoclax and Azacitidine, Achieved a 100% Clinical Benefit Rate in Venetoclax Treatment Naïve AML Patients